We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Innovative Processing Technology Prepares Autologous Fat Grafts

By HospiMedica International staff writers
Posted on 10 Aug 2010
A tissue processing technology facilitates fast, safe, and precise preparation of a patient's own fat for grafting procedures in cosmetic and reconstructive surgery.

The Cytori PureGraft System uses membrane-based tissue filtration technology that takes only 15 minutes to purify a fat graft ranging from 50 mL to 250 mL, removing excess and unwanted fluid, lipid, blood cells, and debris in a controllable manner. More...
The patient's own fat tissue is rapidly prepared for reinjection and for use in aesthetic contouring. Used within the sterile field, the system filters out everything but the purified fat tissue, without centrifugation or other methods. The fat graft can be used to add volume to facial areas such as cheeks, tear troughs, chin and jowls, as well as reshaping the breasts and enhancing the buttocks.

The system uses a bilaminar-flow filtration technology to ensure a consistent graft. Tissue is injected into the system and is selectively filtered through the first membrane, removing loose blood cells, free lipids, fluid, and other debris resulting from the liposuction process. The second membrane directs the flow of the debris and allows for the draining of the contaminants into a waste bag. The tissue is washed twice with 150 mL of processing solution, which allows the physician to control the hydration level of the graft, important in addressing the varying quality of graft recipient sites and ensure graft quality. After the washing and draining is complete, the concentrated graft tissue can be extracted for use.

When used independently, the PureGraft system rapidly and reliably produces optimal graft tissue for use in fat grafting procedures; in combination with the Celution system, the PureGraft lowers processing times and increases processing volumes, improving the utility and efficiency of both products for soft tissue applications. The PureGraft System and the Celution system are products of Cytori Therapeutics (San Diego, CA, USA) and have received the European Community (CE) Mark of approval.

"The addition of PureGraft to our product portfolio allows us to offer a broad spectrum of autologous fat grafting technologies in Europe,” said Eric Daniels, M.D., managing director of Cytori for Europe and the Middle East. "In addition to Celution System, which enables cell-enriched fat grafting procedures, PureGraft fulfills the need for high quality, sterile tissue for fat grafting procedures, including body contouring.”

Related Links:

Cytori Therapeutics



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.